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Abstract
Purpose Polycystic ovary syndrome (PCOS) is a common
endocrine disorder disease among women in reproductive-age.
Since follicle stimulating hormone (FSH) exerts important bio-
logical functions, the association between PCOS and FSH recep-
tor (FSHR) polymorphisms attracts wide attention. The aim of
this study was to evaluate whether polymorphisms of FSHR at
307 and 680 codons are associated with PCOS patients in China.
Methods Patients with PCOS (n=215) and controls (n=205)
were recruited from Shanxi Province in north China. They are
Han ethnics. Genomic DNAwas isolated from the venous blood.
The Ala307Thr and Ser680Asn polymorphisms of FSHR were
analyzed by polymerase chain reaction–restriction fragment
length polymorphism (PCR–RFLP) and direct DNA sequencing.
Results The distributions of genotype and allele of Ala307Thr
and Ser680Asn polymorphisms of FSHRwere not statistically
different between the PCOS patients and the controls. Analy-
sis of the frequency of FSHR polymorphisms showed no
statistical difference among the PCOS patients with different
obesity standards. Although there were no statistical differ-
ences in the most of the endocrine parameters including LH,
LH/FSH, E2, P and T as well as the clinical pregnancy rate,
there were significant differences in the levels of FSH and
PRL among PCOS patients carrying different genotypes of
Ala307Thr and Ser680Asn polymorphisms.
Conclusion The Ala307Thr and Ser680Asn polymorphisms
of FSHR are not associated with PCOS in Han ethnic Chinese
women in north China. The FSHR polymorphisms was related
to the levels of FSH and PRL but not other PCOS-associated
endocrine hormones as well as clinical pregnancy rate in
PCOS patients of Han Chinese ethnical population.




Polycystic ovary syndrome (PCOS) is a common endocrine
disorder disease among women of reproductive age. The
prevalence of PCOS is 5–10 % and the clinical manifestation
of the disease is diverse [1]. According to the 2003 Rotterdam
criteria [2], the characteristics of PCOS mainly include oligo-
menorrhea or amenorrhea, hyperandrogenism and polycystic
ovary morphology. The pathogenesis of PCOS is not fully
understood. However, the influence of heredity and environ-
ment is considered to be the potential causative factors for the
disease. Recent studies revealed that there are multiple sus-
ceptibility genes associated with PCOS, including growth
hormone receptor exon 3 [3], CYP11A1 [4] and GnRH [5].
Follicle stimulating hormone (FSH) is an important hor-
mone for women and plays a role in the follicle development,
oocyte maturation, and steroidogenesis regulation [6]. It me-
diates FSH receptor (FSHR) through its biological functions
[7]. FSHR belongs to the G-protein coupled receptor family
and consists of 10 exons, 9 introns and the promoter region at
chromosome 2p21 [8]. The level of FSH is controlled by
FSHR, and aberrant FSHR affects ovary and folliculogenesis
[6]. Previous studies revealed a low incidence of gene
mutations for the FSHR gene in nature [9]. Single nucleotide
polymorphisms (SNP) were identified in the FSHR gene [10,
11]. Among them,Ala307Thr and Ser680Asn polymorphisms in
exon 10 have drawn increasing attention. Due to the changes of
nucleotide at 307 and 680 loci, which lead to changes of
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corresponding amino acids, FSHR varies in its biological effects.
Many studies showed that FSHR polymorphisms at positions
307 and 680 may be even more relevant for clinical practice for
the reasons of regulating the ovarian reaction to hormone, con-
trolling ovarian hyperstimulation, changing the menstrual cycle,
and causing premature ovarian failure (POF) and PCOS [12].
However, some researches suggested that the results were
inconsistent with the interrelationship between FSHR polymor-
phisms and PCOS. Gut et al. reported that the Ser680Asn of
FSHR was associated with PCOS in Korean women, whereas
the Ala307Thr was not [6]. On the contrary, a research, done by
Dolfin et al., showed that theAla307Thr of FSHRpolymorphism
was related to PCOS in Italian women [13]. In addition, Unsal
et al. found that the genotye frequencies of the Ala307Thr and
Ser680Asn polymorphisms of FSHRwere not different between
the cases and controls in Turkish adolescent girls [14]. In a recent
study, we also found that the association between FSHR poly-
morphisms and PCOS in China was also lack of consistency [15,
16]. Since these studies were conducted in different geographic
regions and with different ethnic groups, the discrepant results
suggested the FSHR–PCOS interrelationship to be geography
and race specific. In this study, we investigated Ala307Thr and
Ser680Asn polymorphisms of the FSHR gene and the relation-
ship between FSHR polymorphisms and PCOS in the Han
Chinese women in north China.
Materials and methods
Subjects
Both the PCOS patients (n=215) and the controls (n=205)
were recruited by Reproductive Medicine Center, Shanxi
Women and Infants Hospital, Taiyuan, China between January
2012 and January 2013. All subjects were Han ethnic, from the
Shaanxi Province, in north China. The study was approved by
the local Medical Ethical Committee and the people of the
PCOS and the control was consented.
The patients were selected based on the 2003 Rotterdam
criteria [2]. Meanwhile, other diseases which could cause
hyperandrogenism, such as congenital adrenal hyperplasia,
hypothyroidism, androgen-secreting tumors, Cushing’s
syndrome, were excluded.
The controls were infertility patients due to tubal and or
male factors with normal ovarian function.
All of the patients had been ruled out of thyroid
abnormalities, cardiovascular system diseases or other
endocrine metabolic disorder disease.
Clinical measurements
The general medical information was collected and recorded,
including the clinical examination results: age, height, weight,
waist circumference, hip circumference, menstrual history of
fertility, B ultrasound assessment, etc. And the body mass
index (BMI) and waist/hip ratio (WHR) were calculated ac-
cordingly. The clinical hyperandrogenismwas assessed by the
modified Ferriman–Gallwey score (mF–G score) [17].
Transvaginal ultrasonography was used to identify polycystic
ovaries (PCO) on a Aloka Prosound α10 (Tokyo, Japan)
ultrasound machine. According to the description of Xu
[18], all the above clinical measurements were completed by
two physicians. The mean value of what was calculated.
Biochemical measurements
On the 3rd to the 5th day of menstrual cycles, blood samples
were taken between 8 AM and 9 AM after a 12-h overnight fast
and immediately centrifuged and frozen at −80 °C until assayed.
For the amenorrhea patients, blood samples were taken on any
day of menstruation providing no dominat follicle detected
under B-ultrasound. The hormone levels, including follicle-
stimulating hormone (FSH, Reference Value: 4.5~11.0 mIU/
ml), luteinizing hormone (LH, Reference Value:1.7~13.3 mIU/
ml), estradiol (E2, Reference Value: 40.7~220.4 pg/ml), proges-
terone (P, Reference Value: ≤0.87 ng/ml), prolactin (PRL, Ref-
erence Value: 4.1~28.9 ng/ml), and testosterone (T, Reference
Value: 9.8~82.1 ng/dl) were measured by AIA-200 ST Auto-
mated Immunoassay Analyzer (Tosoh Corporation, Tokyo,
Japan). The cut-off level of testosterone >82.1 ng/dL was
defined as biochemical hyperandrogenism.
Plasma glucose (Reference Value: 3.90~6.10 mmol/L)
was detected by the hexokinase (HK) method, and insulin
(Reference Value: 0~28.4 uIU/ml) was detected by the
chemiluminescencemethod. The homeostatic model assessment
Table 1 Primers, annealing temperatures, product sizes, restriction enzymes, and allele sizes
Polymorphism Primer sequence (5′-3′) Tm (°C) Product size Restriction enzyme Allele size Reference
Ala307Thr F: 5′-CCTGCACAAAGACAGTGATG-3′; 55 577 AhdI Ala:403+174 [19]
R: 5′-TGGCAAAGACAGTGAAAAG-3′ Thr:403+143+31
Ser680Asn F: 5′-TTTGTGGTCATCTGTGGCTGC-3′; 60 520 BsrI Asn:520 [20]
R:5′-CAAAGGCAAGGACTGAATTATCATT-3′ Ser:413+107
F forward primer, R reverse primer, Tm annealing temperatures, R reference
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for insulin resistance (HOMA-IR) was calculated as follows:
(fasting insulin × fasting glucose)/22.5. Serum cholesterol
(CHO, Reference Value: ≤5.2 mmol/L), triglycerides (TG, Ref-
erenceValue: ≤1.7mmol/L), high-density lipoprotein-cholesterol
(HDL, Reference Value: >1.03 mmol/L) and low-density lipo-
protein (LDL, Reference Value: <3.34 mmol/L) levels were
measured using the precipitation and enzymatic method.
Genotyping
Genomic DNAwas extracted from heparinized venous blood
using E.Z.N.A Blood DNA Kit (Omega, Bio-Tek, Norcross,
GA, USA) according to the manufacturer’s instructions.
Polymerase chain reaction (PCR) was performed in a total
volume of 50μl containing 100 ng of genomic DNA, 0.3M of
forward and reverse primers, 0.2 mM of dNTP, 2.5 unit of Taq
DNA polymerase, and 2 mM of MgSO4. The PCR amplifica-
tion was initiated at 94 °C for 5 min, followed by 30 cycles
consisting of denaturing at 94 °C for 30 s, annealing at 55 °C
(for Ala307Thr) or 60 °C (for Ser680Asn) for 30 s, and
elongation at 72 °C for 1 min, and a final step at 72 °C for
10 min. All PCR products were subjected to direct DNA
sequencing, and 15 % of PCR products were subjected to
restriction enzyme digestion for validation by PCR-restriction
fragment length polymorphism (PCR-RFLP). Restriction en-
zymes Ahd I and Bsr I (all from New England Biolabs,
Ipswich, MA, USA) were used for Ala307Thr and
Ser680Asn, respectively. Ahd I digestion was performed at
37 °C for 4 h, followed by inactivation at 65 °C for 20 min.
Bsr I digestion was performed at 65 °C for 4 h, followed by
inactivation at 80 °C for 20 min. Both PCR and enzyme
digested products were evaluated by electrophoresis in 2 %
and 4 % agarose gels, respectively. The PCR primers, anneal-
ing temperatures, product sizes, restriction enzymes, and allele
sizes are shown in Table 1 [19, 20].
Statistical analysis
Statistical analysis was performed using SPSS Statistics
Version 13.0. Student’s t-test or Mann–Whitney U test
Table 2 Baseline characteristics of all subjects
Variable Controls (n=205) Cases (n=215) p value
Age (year) 31.06±4.89 30.02±4.92 0.163a
Weight (kg) 59.19±7.75 63.40±11.31 0.023b
Height (cm) 161.60±4.45 161.66±5.70 0.979b
BMI (kg/m2) 22.77±3.96 24.49±4.26 0.007a
Waist (cm) 80.50±7.88 92.38±9.46 0.058a
Hip (cm) 96.75±7.52 103.59±6.92 0.076a
WHR 0.83±0.06 0.89±0.07 0.009a
Menarche age (year) 13.66±1.26 13.04±1.20 0.001b
mF-G score 8.51±0.09 8.79±1.20 0.678b
FSH (mIU/ml) 8.81±5.96 8.79±10.09 0.009b
LH (mIU/ml) 5.44±3.97 7.23±4.36 <0.001b
LH/FSH 0.81±0.76 1.04±4.36 <0.001b
E2 (pg/ml) 56.99±34.51 55.45±24.82 0.385b
P (ng/ml) 0.85±2.62 2.39±10.82 0.441b
T (ng/dl) 37.52±19.31 54.17±27.70 <0.001b
PRL (ng/ml) 16.74±9.72 14.84±12.32 0.026b
Fasting insulin (mIU/ml) 6.92±3.57 10.97±6.45 0.727b
Fasting glucose (mmol/l) 5.13±0.58 5.53±0.94 0.015b
HOMA-IR 1.45±1.13 2.17±1.65 <0.001b
CHO (mmol/l) 4.42±0.64 4.17±0.36 0.058a
TG (mmol/l) 1.34±0.16 1.88±1.20 0.027b
HDL (mmol/l) 1.43±0.59 1.20±0.23 0.022a
LDL (mmol/l) 2.44±0.44 2.25±0.15 0.007a
BMIbodymass index,WHRwaist/hip ratio,mF–G scoremodified Ferriman–Gallwey score, FSH follicle-stimulating hormone, LH luteinizing hormone,
E2 estradiol, P progesterone, T testosterone, PRL prolactin, HOMA-IR homoeostasis model assessment, CHO cholesterol, TG triglycerides, HDL high-
density lipoprotein, LDL low-density lipoprotein
a Student’s t-test
bMann–Whtitney U test
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was used to analyze the differences of two continuous vari-
ables. ANOVA and Kruskal–Wallis tests were used to analyze
the differences among multiple (>2) groups. Genotype fre-
quencies were tested for Hardy–Weinberg equilibrium. Chi-
squared test was used to analyze the differences in genotype
and allele frequencies between PCOS and controls. Results
were expressed as percentage and/or mean ± standard devia-
tion (SD). A p-value <0.05 was considered statistically signif-
icant. Linkage disequilibrium (LD) was estimated using D’
and r2 on SHEsis (http://analysis2.bio-x.cn/myAnalysis.php).
Results
A total of 215 PCOS patients and 205 controls were recruited
in this study. All subjects were Han ethnics in Shanxi Province
of north China. The baseline characteristics of the subjects
were shown in Table 2. The levels of Weight, BMI, WHR,
LH, LH/FSH, T, Fasting glucose, HOMA-IR and TG were
higher whereas the levels of Menarche age, FSH, PRL, HDL
and LDLwere lower in the PCOS patients than in the controls.
There were no significant differences between the PCOS
Fig. 2 a Electrophoretogram of DNA fragments for Ser680Asn poly-
morphism after digestion with Bsr I. Homozygote A/Awas shown by the
band of 520 bp. Homozygote G/G was shown by the bands of 413 bp and
107 bp. Heterozygote A/Gwas shown by the bands of 520 bp, 413 bp and
107 bp. bDNA sequencing of the Ser680Asn polymorphisms (AA, AG
and GG) as indicated by arrows. The lane marked M is the marker of
DNA. The lane marked P is the DNA of PCOSwithout enzyme digestion
Fig. 1 a Electrophoretogram of DNA fragments for Ala307Thr poly-
morphisms after digestion with Ahd I. Homozygote A/A was shown by
the bands of 403 bp, 143 bp and 31 bp. Homozygote G/G was shown by
the bands of 403 bp and 174 bp. Heterozygote A/G was shown by the
bands of 403 bp, 174 bp, 143 bp and 31 bp. Note that the 31 bp bands
were run off the gel. b DNA sequencing of the Ala307Thr polymor-
phisms (AA, AG and GG) as indicated by arrows. The lane marked M is
the marker of DNA. The lane marked P is the DNA of PCOS without
enzyme digestion
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patients and the controls in Age, Height, Waist, Hip, mF-G
score, E2, P, Fasting insulin and CHO (Table 1).
Ala307Thr and Ser680Asn polymorphisms of FSHR were
analyzed by PCR–RFLP and DNA sequencing (Figs. 1 and
2). The distribution of FHSR genotypes and allele frequencies
in PCOS patients and controls were evaluated (Table 3). The
distribution of the polymorphisms was conformed by Hardy–
Weinberg equilibrium test. In PCOS patients, linkage disequi-
librium (D’) between the Ala307Thr and Asn680Ser of FSHR
polymorphisms was 0.932 (r2=0.831), indicating a near-
complete linkage disequilibrium. However, there were no
statistical differences in the allele or genotype frequencies of
the polymorphisms between the PCOS patients and the
controls.
We further analyzed the phenotypes for the Ala307Thr and
Ser680Asn polymorphisms in the PCOS patients. There were
no statistical differences among the different obesity standards
of the PCOS patients with different FSHR polymorphisms
(Table 4). For the endocrine parameters, there were significant
differences in the level of FSH among the PCOS patients
carrying different genotypes of the two polymorphisms (p=
0.027 for Ser680Asn; p=0.009 for Ala307Thr) and in the
level of PRL among the PCOS patients carrying different
genotypes of the Ser680Asn polymorphisms (p=0.009)
(Table 5). There were no statistical differences in LH, LH/
FSH, E2, P and T. Moreover, no statistical difference was
found in the clinical pregnancy rate among the PCOS patients
carrying different genotypes of the two polymorphisms
(Fig. 3).
Discussion
It has been known that PCOS is a hereditary endocrine disease.
With changes of living environment and increase of social
pressure, the incidence of PCOS gradually increases during
recent years. The clinical manifestations of PCOS patients
appear diverse in different geographic regions and among dif-
ferent races. Up to date, knowledge about PCOS has been
mainly obtained from the studies involving Western popula-
tions. A recent study comparing 547 Chinese women with 427
Dutch women revealed some differences in the phenotypic
characteristics of PCOS between the two ethnic groups [21].
In this study, we assessed the baseline characteristics between
the PCOS patients (n=215) and the controls (n=205) in the Han
ethnic of Shanxi Province in north China. We observed in-
creased levels of Weight, BMI, WHR, LH, LH/FSH, T, Fasting
glucose, HOMA-IR and TG and decreased levels of Menarche
age, FSH, PRL, HDL and LDL in the PCOS patients.
As a complex hereditary endocrine disease, analyses of
major genes associated with PCOS have been attempted for
Table 4 FSHR polymorphisms versus different obesity standards in PCOS patients
Ala307Thr Ser680Asn
AA (n=93) AG (n=95) GG (n=27) p value AA (n=93) AG (n=94) GG (n=28) p value
BMI
<18.5 9 (52.9 %) 6 (35.3 %) 2 (11.8 %) 0.68 6 (50.0 %) 3 (25.0 %) 3 (25.0 %) 0.66
18.5–24 29 (36.2 %) 42 (52.5 %) 9 (11.2 %) 33 (41.8 %) 35 (44.3 %) 11 (13.9 %)
24–28 35 (45.5 %) 31 (40.3 %) 11 (14.3 %) 29 (40.8 %) 32 (45.1 %) 10 (14.1 %)
>28 20 (48.8 %) 16 (39.0 %) 5 (12.2 %) 25 (47.2 %) 24 (45.3 %) 4 (7.5 %)
WHR
<0.85 31 (48.4 %) 29 (45.3 %) 4 (6.2 %) 0.18 35 (47.9 %) 34 (46.6 %) 4 (5.5 %) 0.06
>0.85 62 (41.4 %) 66 (43.7 %) 23 (15.2 %) 58 (40.8 %) 60 (42.3 %) 24 (16.9 %)
p values from chi-squared test on the different genotypes of FSHR polymorphisms
Table 3 Genotype distribution and allele frequency of FSHR
polymorphism
Genotype Cases (n=215) Controls (n=205) p value
A307T(rs6165)
Thr/Thr(AA) 93 (43.3 %) 91 (44.4 %) 0.133
Ala/Thr(AG) 95 (44.2 %) 100 (48.8 %)
Ala/Ala(GG) 27 (12.6 %) 14 (6.8 %)
H-W test 0.721 0.052
Allele frequency
Ala(G) 149 (15.3 %) 128 (31.5 %) 0.29
Thr(A) 281 (65.2 %) 282 (69.3 %)
N680S(rs6166)
Asn/Asn(AA) 93 (43.3 %) 94 (45.9 %) 0.069
Ser/Asn(AG) 94 (43.7 %) 98 (47.8 %)
Ser/Ser(GG) 28 (13.0 %) 13 (6.3 %)
H-W test 0.581 0.057
Allele frequency
Asn(A) 280 (69.8 %) 286 (69.8 %) 0.152
Ser(G) 150 (30.2 %) 124 (30.2 %)
p values from chi-squared test
H–W testHardy–Weinberg equilibrium test
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better understanding of the etiology of the disease. Since it
plays an important role in FSH signal transduction, FSHR has
been extensively studied including its gene structure. The
polymorphisms at the 307 and 680 loci on exon 10 of FSHR
have become an attracting topic in recent years. A study
from Shanghai, a metropolitan city in southeast China,
showed a significant association between PCOS patients and
Ser680Asn but not Ala307Thr polymorphisms of FSHR in the
Han ethnic women [15]. To investigate whether this observation
also exists in different geographic regions of China, we recruited
patients with the same Han ethnic from Shanxi Province in
north China. However, we failed to observe any association
between PCOS patients and the Ser680Asn polymorphisms of
FSHR. Our results are consistent with a recently reported study
conducted in Xi’an, a city near Shanxi Province within the same
north China region [16] and a study performed in a different
geographic region (Netherlands) and with different ethnical
women (Caucasian) [5]. Therefore, studies using different eth-
nical populations and/or conducted in different geographic re-
gions may lead to different results of the interrelationship be-
tween FSHR polymorphisms and PCOS.
Obesity and abdominal adiposity are typical clinical
manifestations of PCOS patients. It has been reported
that approximately 50 % of PCOS women are over-
weight or obese and most of them have the abdominal
phenotype [22]. Based on BMI and WHR, the criteria
used for obesities [23, 24], we investigated whether
there was a correlation between obesity and the FSHR
polymorphisms in PCOS patients. We have observed no
correlation between the different obesity standard of
PCOS patients and the genotypes of FSHR polymor-
phism. A panel of endocrine hormones was analyzed
in relation to the genotypes of Ala307Thr and
Ser680Asn polymorphisms in the PCOS patients. We
have observed that the both FSHR polymorphisms were re-
lated to the level of FSH. In addition, the result showed that
the Ser680Asn polymorphism was correlated with the level of
PRL. Interestingly, there was no significant difference be-
tween the clinical pregnancy rate and the different genotypes
of FSHR polymorphisms.
In conclusion, our results indicate that there is no
association between the Ala307Thr and Ser680Asn
polymorphisms of FSHR and PCOS patients in Han
ethnical population from Shanxi Province in north Chi-
na. In addition, the FSHR polymorphisms are associated
with the levels of FSH and PRL.
Fig. 3 Clinical pregnancy rate of PCOS patients carrying different FSHR polymorphisms
Table 5 FSHR polymorphisms versus endocrine parameters in PCOS patients
Ala307Thr Ser680Asn
AA (n=93) AG (n=95) GG (n=27) p value AA (n=93) AG (n=94) GG (n=28) p value
FSH (mIU/ml) 7.07±2.54 7.48±1.77 13.22±16.64 0.009 7.12±2.55 7.57±1.89 13.71±17.46 0.027
LH (mIU/ml) 7.19±4.48 7.88±5.78 7.53±4.71 0.823 7.14±4.45 7.22±4.69 8.45±4.89 0.445
LH/FSH 1.11±0.81 1.09±0.79 0.89±0.60 0.539 1.06±0.66 0.99±0.65 0.99±0.63 0.924
E2 (pg/ml) 55.60±15.43 55.32±34.72 53.77±19.81 0.301 55.59±15.57 56.32±32.99 52.55±20.21 0.415
P (ng/ml) 1.30±5.52 2.61±11.32 4.65±14.05 0.718 1.31±5.64 0.79±2.00 0.44±0.13 0.927
T (ng/dl) 60.19±29.37 51.91±28.34 44.76±24.86 0.115 59.40±29.85 53.69±27.62 45.52±25.05 0.282
PRL (ng/ml) 17.20±15.68 12.07±7.38 16.55±6.46 0.052 17.73±15.69 11.70±6.93 17.01±6.80 0.009
p values from ANOVA test on the different genotypes of FSHR polymorphisms
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